

Advancing pipeline

AI platform	Product Candidate (Delivery modality)	Stage of Development				Anticipated Key Milestone
		Pre-clinical	Phase 1	Phase 2	Phase 3	
PIONEER Patient-specific cancer immunotherapies	EVX-01 (Liposomal/Peptide) Metastatic Melanoma			2a	2b	H1 2022 First-patient-first-visit Phase 2b
	EVX-02 (DNA) Adjuvant Melanoma				MSD	H1 2023: Clinical readout
	EVX-03 (Targeted DNA) NSCLC					H2 2022: Regulatory filing
EDEN Vaccines against bacterial diseases	EVX-B1 (Adjuvanted Recombinant Proteins) <i>S. aureus</i> , SSTI					H2 2022: Regulatory filing
	EVX-B2 <i>Multiple bacteria</i>					H1 2022: Select second bacterial product candidate
RAVEN Vaccines against viral diseases	EVX-VI (DNA/mRNA) <i>Multiple viruses</i>					H2 2022: Select first viral product candidate

Anticipated Key Milestones 2022-23

AI Platform	Indication	Product Candidate	Phase	2022	2023	2024
PIONEER Immuno-oncology	Metastatic Melanoma	EVX-01 (with MSD)	Phase 2b	H1 First-patient-first-visit	H2 Interim readout	Readout, 1 year
PIONEER Immuno-oncology	Adjuvant Melanoma	EVX-02	Phase 1/2a		H1 Clinical readout	
PIONEER Immuno-oncology	NSCLC	EVX-03	Phase 1/2	H2 Regulatory filing	H1 FPFV H2 Interim Immune readout/safety	Interim Clinical readout
BUSINESS/PARTNERSHIP		All	Pre-clinical to Phase 2	Partnerships on programs and technologies	Partnerships on programs and technologies	Partnerships on programs and technologies
EDEN Infectious diseases	Staph. Aureus	EVX-B1	Pre-clinical	H2 Regulatory filing	Phase 1/2	
EDEN Infectious diseases		EVX-B2	Pre-clinical	H1 Selection of second bacterial target	Partnership	
RAVEN Infectious diseases		EVX-V1	Pre-clinical	H2 Selection of first viral product candidate	Partnership	